SCHEDULE: State Street Discloses 5.1% Stake in Ultragenyx

State Street Corporation has reported beneficial ownership of 5.1% of Ultragenyx Pharmaceutical Inc.'s common stock as of March 31, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating it beneficially owns 5,021,441 shares of Ultragenyx Pharmaceutical Inc. common stock.
• This ownership represents 5.1% of the class of securities.
• The filing date is May 12, 2026, with the event date requiring the filing being March 31, 2026.
• State Street Corporation is identified as a holding company (HC) and its subsidiaries involved in this ownership include SSGA FUNDS MANAGEMENT, INC., STATE STREET GLOBAL ADVISORS EUROPE LIMITED, STATE STREET GLOBAL ADVISORS LIMITED, STATE STREET GLOBAL ADVISORS TRUST COMPANY, and STATE STREET GLOBAL ADVISORS, LTD.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of institutional ownership and does not provide new operational or financial performance information.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by State Street Corporation signifies a substantial institutional holding in Ultragenyx Pharmaceutical Inc., a biotechnology company. Such filings are common for large asset managers and indicate a significant passive investment.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can be viewed positively as a sign of confidence in the company's long-term prospects.

Key Dates

Keywords

Ultragenyx Pharmaceutical Inc, State Street Corporation, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing